

Supplementary Materials: Effect of clinical parameters on risk of death from cancer after radical prostatectomy in men with localized and locally advanced prostate cancer

Daimantas Milonas, Tomas Ruzgas, Zilvinas Venclovas, Daniele Jonusaite, Aivaras Jonas Matijosaitis, Darius Trumbeckas, Edmundas Varpiotas, Stasys Auskalnis, Darijus Skaudickas, Ramunas Mickevicius, Kestutis Vaiciunas, Jonas Mickevicius and Mindaugas Jievaltas

Table S1. Pathological patient characteristics according age <65 vs. ≥65 years.

Parameter	<65 Years (<i>n</i> = 1309)	≥65 Years (<i>n</i> = 1112)	<i>p</i> Value
Pathological stage (pT), <i>n</i> (%)			
T2	875 (66.8)	698 (62.8)	0.080
T3a	345 (26.4)	318 (28.6)	
T3b-4	89 (6.8)	96 (8.6)	
PSA, ng/ml – median (IQR)			
	6.05 (4.5-9)	6.6 (5-10)	<0.001
Lymph node status, <i>n</i> (%)			
pN0	331 (25.3)	382 (34.4)	<0.001
pN1	37 (2.8)	46 (4.1)	
Unknown	941 (71.9)	684 (61.5)	
GG after RP, <i>n</i> (%)			
1	337 (25.8)	293 (26.5)	<0.001
2	727 (55.6)	559 (50.5)	
3	149 (11.4%)	102 (9.2)	
4	42 (3.2%)	67 (6.1)	
5	53 (4.1%)	85 (7.7)	
Unknown	1 (0.1%)	6 (0.4%)	
Surgical margins status, <i>n</i> (%)			
Negative	885 (67.6)	732 (65.8)	0.582
Positive	366 (28.0)	332 (29.9)	
Unknown	58 (4.4)	48 (4.3)	

PSA – prostate specific antigen, GG – International Society of Urological Pathology Grade Groups, RP radical prostatectomy, pN0 – negative lymph node, pN1 – positive lymph node.

Table S2. Cumulative 5- and 10-year mortality from cancer and other causes in all cohort and sub-groups stratified according to grade group, age and pathological stage.

	5-yr mortality (95%CI)		10-yr mortality (95%CI)	
	Prostate cancer	Other causes	Prostate cancer	Other causes
GG1				
<65yr + pT2-3a	0.1 (0.03-0.3)	3.8 (3.0-5.3)	0.4 (0.1-1.3)	11.1 (8.4-13.3)
≥65yr + pT2-3a	0.2 (0.06-0.6)	8.1 (6.5-10.9)	1.0 (0.3-2.9)	22.5 (17.7-26.1)
<65yr + pT3b-4	0.4 (0.1-1.5)	8.8 (3.9-13.8)	2.0 (0.6-6.4)	23.8 (11.8-30.1)
≥65yr + pT3b-4	0.9 (0.3-3.6)	18.0 (9.4-24.7)	4.8 (1.4-16.9)	43.2 (25.7-51.5)
GG2				
<65yr + pT2-3a	0.2 (0.1-0.4)	3.6 (2.9-4.8)	1.1 (0.6-1.9)	10.1 (7.9-12.3)
≥65yr + pT2-3a	0.5 (0.3-0.9)	7.5 (6.3-9.9)	2.5 (1.4-4.4)	20.4 (16.5-24.4)
<65yr + pT3b-4	1.0 (0.5-2.3)	7.9 (4.3-10.9)	5.1 (2.7-9.6)	20.1 (11.8-26.2)
≥65yr + pT3b-4	2.5 (1.1-5.3)	16.1 (9.2-21.9)	11.8 (6.3-22.0)	35.2 (25.6-45.7)
GG3				
<65yr + pT2-3a	0.5 (0.2-1.4)	3.1 (1.8-4.9)	2.5 (1.0-6.2)	8.2 (5.1-12.5)
≥65yr + pT2-3a	1.2 (0.5-2.8)	6.5 (4.2-9.8)	5.9 (2.7-12.9)	15.9 (10.7-25.5)
<65yr + pT3b-4	2.5 (0.9-6.6)	6.1 (2.8-10.8)	11.8 (4.1-34.3)	12.4 (7.9-26.2)
≥65yr + pT3b-4	5.8 (2.5-13.5)	11.9 (6.6-20.2)	26.1 (12.3-55.2)	19.3 (17.2-47.5)
GG4				
<65yr + pT2-3a	0.9 (0.4-2.2)	4.8 (2.5-7.8)	4.5 (2.1-10.0)	12.2 (7.7-17.8)
≥65yr + pT2-3a	2.2 (0.9-5.3)	9.9 (6.2-14.2)	10.6 (4.8-23.3)	22.4 (15.1-36.9)
<65yr + pT3b-4	4.4 (1.7-11.9)	9.0 (4.7-14.1)	20.5 (11.1-37.8)	15.7 (12.1-35.3)
≥65yr + pT3b-4	10.3 (4.1-26.2)	16.8 (9.5-29.5)	42.4 (25.9-69.2)	20.1 (16.8-40.2)
GG5				
<65yr + pT2-3a	3.1 (1.4-6.8)	5.8 (2.2-7.5)	14.8 (7.4-29.8)	10.5 (5.9-19.4)
≥65yr + pT2-3a	7.3 (4.3-12.7)	11.3 (4.9-14.8)	32.0 (17.4-58.8)	15.2 (12.8-36.6)
<65yr + pT3b-4	14.4 (7.7-27.1)	6.1 (3.9-14.1)	54.6 (34.3-86.9)	0 (0-36.4)
≥65yr + pT3b-4	31.3 (19.3-50.6)	8.3 (4.4-13.7)	84.9 (69.8-100)	0 (0-59.9)

CI – confidence interval, GG – International Society of Urological Pathology Grade Groups, pT – pathological stage.